UAE Becomes Second Country Globally to Approve Dual-Action Heart Failure Drug Inpefa
核心洞察
The UAE's Emirates Drug Establishment has approved Inpefa (sotagliflozin), making it the second country worldwide to authorize this dual SGLT1 (搜索)/SGLT2 (搜索) inhibitor for heart failure treatment.
Clinical trials demonstrate the drug reduces cardiovascular deaths, heart failure hospitalizations, and urgent medical visits, with benefits emerging within weeks of treatment initiation.
The approval addresses a growing heart failure burden in the UAE driven by high rates of diabetes, hypertension, and coronary artery disease, particularly affecting younger populations.
The UAE has become the second country globally to approve Inpefa (sotagliflozin), a dual-action heart failure treatment that represents a significant advancement in cardiovascular care. The Emirates Drug Establishment (EDE) announced the authorization on Monday, marking a milestone in the nation's commitment to healthcare innovation.
Breakthrough Dual-Mechanism Treatment
Inpefa (sotagliflozin) is the first approved treatment for heart failure that functions as both an SGLT1 (搜索) and SGLT2 (搜索) inhibitor. Unlike other drugs in the same class, sotagliflozin works on both the kidneys and the gut, affecting how glucose is absorbed and excreted. This dual mechanism may offer additional benefits compared to established treatments.
Clinical trials have demonstrated that the oral medication reduces deaths linked to cardiovascular disease, decreases hospital admissions for heart failure, and cuts down on urgent medical visits. The treatment is intended for adults with heart failure, type 2 diabetes, chronic kidney disease, or other heart-related risks.
Dr. Brajesh Mittal, head of cardiology at Medcare Hospital Al Safa (搜索), confirmed that trial data showed "meaningful reductions in cardiovascular death and heart failure hospitalisation, with benefits emerging within weeks." He noted that studies suggest the drug can be started safely in patients while they are still in hospital.
Addressing Growing Healthcare Burden
Heart failure represents a growing problem in the UAE, driven by high rates of diabetes, hypertension and coronary artery disease. The condition, in which the heart cannot pump blood effectively, is a chronic and serious ailment that causes major health problems and increased hospital visits.
The approval comes as UAE doctors report diagnosing cardiac problems up to 15 years earlier than elsewhere, with work stress and unhealthy lifestyles triggering a rise in younger people with heart disease. "Heart failure is a major concern and faster access to effective treatments can improve outcomes," Dr. Mittal emphasized.
Early Implementation and Future Adoption
Some UAE hospitals have already begun using the newly approved treatment. "In our hospital, it is available and being prescribed, and some patients have already started treatment," Dr. Mittal reported. The drug was generally well tolerated in trials, with a safety profile consistent with expectations for this class of medications.
However, widespread adoption may take time. Dr. Jan Niclas Strickling, a consultant cardiologist at Medcare Hospital Al Safa (搜索), explained that "approval and real-world use are not the same thing. It is not yet being widely prescribed across all settings."
Access will depend on how quickly insurers, hospitals and pharmacies move to adopt the drug. "Before it becomes routine, insurance coverage, hospital formularies and availability all need to be in place. That process can vary between healthcare providers and can take time," Dr. Strickling noted.
Clinical Applications and Patient Selection
The drug may be most useful for patients who remain unwell despite standard therapy, particularly those at high risk of repeated hospital admissions. "Every hospitalisation worsens long-term outcomes for heart-failure patients," Dr. Strickling observed.
Dr. Georgie Thomas, a consultant cardiologist at Burjeel Hospital (搜索), indicated that the strongest evidence for sotagliflozin exists in patients whose heart failure is linked to diabetes. "For those patients, it would likely be my first choice," he said. "For non-diabetic patients, the SGLT2 (搜索) inhibitors we already use work just as well."
However, Dr. Thomas urged caution against overselling the approval, advising patients not to delay existing treatment in anticipation of the new drug. "This is not a eureka moment – it's another useful addition," he emphasized.
Regulatory Leadership and Global Context
Dr. Fatima Al Kaabi, Director General of the Emirates Drug Establishment, highlighted that the approval demonstrates the UAE's commitment to medical advances. "The Establishment attaches utmost priority to developing flexible and effective regulatory frameworks, particularly for advanced therapies," she stated.
The approval reflects the UAE's position at the forefront of pharmaceutical regulation, with Al Kaabi noting the commitment to "adopting global best practices in pharmaceutical regulation" and developing "an integrated and sustainable healthcare ecosystem built on innovation."
Dr. John Dennis, an associate professor of health data science at the University of Exeter, confirmed that SGLT2 (搜索)-inhibitor drugs are "very well-established" in treating Type II diabetes, with increasing use for heart failure in recent years. However, he noted that dual-action drugs like sotagliflozin are still in "very early stage" development.
Ayman Mokhtar, Regional President of Viatris for the MENA and Eurasia region, emphasized the company's commitment to making Inpefa accessible to patients who need it most through their strong presence in the UAE.